[go: up one dir, main page]

PT3240805T - Recetor de antigénio quimérico de porta ou biespecífico responsivo a cd19 e cd20 - Google Patents

Recetor de antigénio quimérico de porta ou biespecífico responsivo a cd19 e cd20

Info

Publication number
PT3240805T
PT3240805T PT158708180T PT15870818T PT3240805T PT 3240805 T PT3240805 T PT 3240805T PT 158708180 T PT158708180 T PT 158708180T PT 15870818 T PT15870818 T PT 15870818T PT 3240805 T PT3240805 T PT 3240805T
Authority
PT
Portugal
Prior art keywords
bispecific
gate
antigen receptor
chimeric antigen
receptor responsive
Prior art date
Application number
PT158708180T
Other languages
English (en)
Original Assignee
Univ California
Seattle Childrens Hospital Dba Seattle Childrens Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Seattle Childrens Hospital Dba Seattle Childrens Res Inst filed Critical Univ California
Publication of PT3240805T publication Critical patent/PT3240805T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT158708180T 2014-12-15 2015-12-14 Recetor de antigénio quimérico de porta ou biespecífico responsivo a cd19 e cd20 PT3240805T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462091854P 2014-12-15 2014-12-15

Publications (1)

Publication Number Publication Date
PT3240805T true PT3240805T (pt) 2025-01-28

Family

ID=56127437

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158708180T PT3240805T (pt) 2014-12-15 2015-12-14 Recetor de antigénio quimérico de porta ou biespecífico responsivo a cd19 e cd20

Country Status (10)

Country Link
US (6) US11253546B2 (pt)
EP (2) EP3240805B1 (pt)
CA (1) CA3008162A1 (pt)
DK (1) DK3240805T3 (pt)
ES (1) ES3008782T3 (pt)
FI (1) FI3240805T3 (pt)
LT (1) LT3240805T (pt)
PT (1) PT3240805T (pt)
SM (1) SMT202500043T1 (pt)
WO (1) WO2016100232A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
PT3240805T (pt) * 2014-12-15 2025-01-28 Univ California Recetor de antigénio quimérico de porta ou biespecífico responsivo a cd19 e cd20
EP3234120A4 (en) 2014-12-15 2018-05-16 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
EP4169945A1 (en) 2015-10-30 2023-04-26 The Regents of the University of California Transforming growth factor-beta-responsive polypeptides and their methods for use
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
US11453712B2 (en) * 2016-09-02 2022-09-27 Lentigen Technology Inc. Compositions and methods for treating cancer with DuoCARs
AU2017341047B2 (en) 2016-10-07 2024-10-10 Novartis Ag Chimeric antigen receptors for the treatment of cancer
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
AU2018309735B2 (en) 2017-07-31 2025-03-13 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
CN109423495A (zh) * 2017-08-24 2019-03-05 上海恒润达生生物科技有限公司 一种双靶向嵌合抗原受体及其用途
JP2021506305A (ja) * 2017-12-22 2021-02-22 ブルーバード バイオ， インコーポレイテッド 多価キメラ抗原受容体
US10561686B2 (en) 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
CN108285486A (zh) * 2018-01-15 2018-07-17 浙江阿思科力生物科技有限公司 以cd20为靶点的特异性抗体、car-nk细胞及其制备和应用
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
US12258381B2 (en) 2018-02-09 2025-03-25 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US20210230289A1 (en) * 2018-06-12 2021-07-29 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
WO2020123691A2 (en) 2018-12-12 2020-06-18 Kite Pharma, Inc Chimeric antigen and t cell receptors and methods of use
CN113330038A (zh) * 2019-01-22 2021-08-31 亘喜生物科技（上海）有限公司 Cd20组合靶向的工程化免疫细胞
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
MX2022010936A (es) 2020-03-05 2022-11-16 Neotx Therapeutics Ltd ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas.
CN113402612A (zh) * 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
EP4127188A4 (en) * 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
CN117396607A (zh) 2020-12-30 2024-01-12 阿劳诺斯治疗公司 包含多顺反子表达盒的重组载体及其使用方法
WO2022165461A1 (en) * 2021-01-27 2022-08-04 H. Lee Moffitt Cancer Center And Research Institute Inc. Bi-specific car t cells for b cell malignancies
KR20240028975A (ko) * 2021-04-08 2024-03-05 사나 바이오테크놀로지, 인크. Cd8-특이적 항체 구조체들 및 이의 조성물
EP4384549A1 (en) * 2021-08-12 2024-06-19 Cellogen Therapeutics Pvt. Ltd. Chimeric antigen receptors (car) for b cell malignancies
WO2024031071A2 (en) * 2022-08-04 2024-02-08 Immpact-Bio, Ltd. Methods of manufacturing chimeric antigen receptor t cells
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1864312A (en) * 1927-10-12 1932-06-21 Int Harvester Co Safety device for corn shredders
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
EP0417563B1 (de) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
KR100249937B1 (ko) 1991-04-25 2000-04-01 나가야마 오사무 인간 인터루킨-6 수용체에 대한 재구성 인간 항체
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5138941A (en) 1991-06-28 1992-08-18 Strauss Frederick J Wooden crusher for recyclable metal cans
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US7166423B1 (en) 1992-10-21 2007-01-23 Miltenyi Biotec Gmbh Direct selection of cells by secretion product
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US6074841A (en) 1996-08-19 2000-06-13 Millennium Biotherapeutics, Inc. Don-1 gene and polypeptides and uses therefor
US5958703A (en) 1996-12-03 1999-09-28 Glaxo Group Limited Use of modified tethers in screening compound libraries
US6132722A (en) 1997-05-07 2000-10-17 Bristol-Myers Squibb Company Recombinant antibody-enzyme fusion proteins
EP2386629A1 (en) 1997-10-14 2011-11-16 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7066469B2 (en) 2002-08-06 2006-06-27 University of Kentucky Research Foundation Board of Supervisors of Louisiana State University Seal assembly for machinery housing
US20040043949A1 (en) 2002-08-30 2004-03-04 Christopher Richardson Therapeutic system targeting pathogen proteases and uses thereof
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
KR20090088973A (ko) 2002-10-17 2009-08-20 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2004085611A2 (en) 2003-03-21 2004-10-07 The Research Foundation Of State University Of New York Model for mutually exclusive domain folding molecular switch
WO2005004809A2 (en) 2003-07-01 2005-01-20 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
RU2006101216A (ru) 2003-08-01 2007-07-20 Амген Инк. (US) Кристаллические полипептиды 2 фактора некроза опухолей
US20050050200A1 (en) 2003-09-02 2005-03-03 Kabushiki Kaisha Toshiba Computer system and cluster system program
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
AU2004292180A1 (en) 2003-11-13 2005-06-02 Genentech, Inc. Screening assays and methods of tumor treatment
JP5128935B2 (ja) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド ヒト化抗ＴＧＦ−β抗体
EP1810980A1 (en) 2004-10-28 2007-07-25 Osaka University Interleukin-6 inhibitors
CN101163502A (zh) 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
US20090068158A1 (en) 2005-12-09 2009-03-12 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
AU2006325706B2 (en) 2005-12-16 2012-03-29 Novartis Ag Control of intraocular pressure using ALK5 modulation agents
HRP20211788T1 (hr) 2008-08-26 2022-02-18 City Of Hope Postupak i pripravci za poboljšanje anti-tumorskog efektorskog funkcioniranja t stanica
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010151341A1 (en) 2009-06-24 2010-12-29 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
CA2764729C (en) 2009-06-26 2019-04-02 Sea Lane Biotechnologies, Llc Expression of surrogate light chains
EP2566954B2 (en) 2010-05-04 2022-11-02 Yeda Research and Development Co. Ltd. Immunotherapy using redirected allogeneic cells
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
NZ608813A (en) 2010-09-01 2014-11-28 Genzyme Corp Treatment of myocardial infarction using tgf - beta antagonists
TWI603738B (zh) 2010-11-08 2017-11-01 建南德克公司 皮下投予抗－ｉｌ－６受體抗體
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
CN102875678B (zh) 2011-07-13 2014-08-06 无锡天演生物技术有限公司 全人源抗人cd20单抗分子及其应用
LT2794658T (lt) 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
ES2774160T3 (es) * 2012-02-13 2020-07-17 Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
MX2015000426A (es) 2012-07-13 2015-07-14 Univ Pennsylvania Incremento de actividad de celulas t car mediante cointroduccion de un anticuerpo biespecifico.
CA3177394A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
WO2014055836A2 (en) 2012-10-04 2014-04-10 Research Development Foundation Serine protease molecules and therapies
KR101911438B1 (ko) 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
EP2730289A1 (en) 2012-11-07 2014-05-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel immunoproteases
CN104955838B (zh) 2012-11-21 2021-02-02 詹森生物科技公司 双特异性EGFR/c-Met抗体
JP6571527B2 (ja) 2012-11-21 2019-09-04 ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドＷｕｈａｎ Ｙｚｙ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 二重特異性抗体
DK3300745T3 (da) 2013-02-15 2019-11-04 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
BR112015021595A2 (pt) 2013-03-11 2017-10-10 Genzyme Corp anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno
CN105452287A (zh) 2013-04-17 2016-03-30 贝勒医学院 免疫抑制性TGF-β信号转换器
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
AU2014376328A1 (en) 2014-01-13 2016-07-21 Christine E. BROWN Chimeric antigen receptors (CARs) having mutations in the Fc spacer region and methods for their use
EP3505623A1 (en) 2014-02-14 2019-07-03 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
WO2015128653A2 (en) 2014-02-27 2015-09-03 Ucl Business Plc Ligand
JP2017515464A (ja) 2014-04-10 2017-06-15 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート 細胞免疫療法のための方法および組成物
CN106459924A (zh) 2014-04-23 2017-02-22 得克萨斯州大学系统董事会 用于疗法中的嵌合抗原受体(car)及其制备方法
WO2015179801A1 (en) 2014-05-23 2015-11-26 University Of Florida Research Foundation, Inc. Car based immunotherapy
MX2017004603A (es) 2014-10-07 2017-06-30 Cellectis Metodo para modular actividad de celulas inmunes inducidas por car.
US20170333480A1 (en) 2014-11-05 2017-11-23 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
CN107206025A (zh) 2014-12-03 2017-09-26 朱诺治疗学股份有限公司 用于过继细胞治疗的方法和组合物
BR112017012502B1 (pt) 2014-12-12 2020-09-15 Bluebird Bio, Inc. Polinucleotídeo, polipeptídeo de car codificado pelo dito polinucleotídeo, vetor compreendendo o dito polinucleotídeo, composição compreendendo o dito vetor e método para geração de uma célula imune efetora compreendendo um car
PT3240805T (pt) * 2014-12-15 2025-01-28 Univ California Recetor de antigénio quimérico de porta ou biespecífico responsivo a cd19 e cd20
EP3234120A4 (en) 2014-12-15 2018-05-16 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
EP3256492A4 (en) 2015-02-09 2018-07-11 University of Florida Research Foundation, Inc. Bi-specific chimeric antigen receptor and uses thereof
PL3280729T3 (pl) * 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
MX2018001568A (es) 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP4169945A1 (en) 2015-10-30 2023-04-26 The Regents of the University of California Transforming growth factor-beta-responsive polypeptides and their methods for use
MA44314A (fr) 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
US12139526B2 (en) 2015-12-03 2024-11-12 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
WO2017172981A2 (en) 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
TWI691596B (zh) 2016-04-01 2020-04-21 美商凱特製藥公司 嵌合抗原和ｔ細胞受體及使用方法
WO2017180993A1 (en) 2016-04-14 2017-10-19 Bluebird Bio, Inc. Salvage chimeric antigen receptor systems
CN105837693A (zh) 2016-05-30 2016-08-10 李斯文 一种基于bcma的抗原嵌合受体及其制备方法和应用
EP4353750A3 (en) 2016-06-24 2024-07-24 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars), compositions and methods thereof
EP4529966A2 (en) 2016-08-29 2025-04-02 Fred Hutchinson Cancer Center Chelating platform for delivery of radionuclides
US11453712B2 (en) 2016-09-02 2022-09-27 Lentigen Technology Inc. Compositions and methods for treating cancer with DuoCARs
CN109963590B (zh) 2016-09-02 2024-03-15 加利福尼亚大学董事会 涉及白介素-6受体α结合单链可变片段的方法和组合物
AU2017341047B2 (en) 2016-10-07 2024-10-10 Novartis Ag Chimeric antigen receptors for the treatment of cancer
BR112019011277A2 (pt) 2016-12-02 2019-10-22 Univ Southern California polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
CN108148863B (zh) 2016-12-05 2019-12-17 上海优卡迪生物医药科技有限公司 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用
KR20200054160A (ko) * 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
MA49403A (fr) * 2017-06-12 2021-03-24 Obsidian Therapeutics Inc Compositions de pde5 et méthodes d'immunothérapie
US11325957B2 (en) 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
AU2018309735B2 (en) 2017-07-31 2025-03-13 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
KR20200071079A (ko) 2017-09-27 2020-06-18 유니버시티 오브 써던 캘리포니아 공동-자극을 위한 신규한 플랫폼, 신규한 car 설계 및 입양 세포 치료를 위한 다른 향상
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
JP2021506305A (ja) 2017-12-22 2021-02-22 ブルーバード バイオ， インコーポレイテッド 多価キメラ抗原受容体
CN111770937A (zh) 2017-12-29 2020-10-13 希望之城 中间位使能t细胞
WO2019134866A1 (en) 2018-01-03 2019-07-11 Molmed Spa Chimeric antigen receptors containing optimal spacer region
CN112912493A (zh) 2018-05-31 2021-06-04 华盛顿大学 用于治疗癌症的嵌合抗原受体t细胞(car-t)
US11123079B2 (en) 2018-06-08 2021-09-21 Boston Scientific Scimed, Inc. Occlusive device with actuatable fixation members
US20210230289A1 (en) 2018-06-12 2021-07-29 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer
CN112292147A (zh) 2018-06-19 2021-01-29 南京传奇生物科技有限公司 工程化的细胞及其用途
US20210269525A1 (en) 2018-06-29 2021-09-02 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ANTI-CD3e ANTIBODIES AND USES THEREOF
US12036242B2 (en) 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
JP2021532818A (ja) 2018-08-06 2021-12-02 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） ハプテン標識細胞によりキメラ抗原受容体ｔ細胞を刺激する方法およびそのための組成物
EP3860642A1 (en) 2018-10-05 2021-08-11 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
CA3109747A1 (en) 2018-10-05 2020-04-09 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
EP4393547A3 (en) 2018-11-30 2024-09-18 Juno Therapeutics, Inc. Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
WO2020123691A2 (en) 2018-12-12 2020-06-18 Kite Pharma, Inc Chimeric antigen and t cell receptors and methods of use
AU2020226401A1 (en) 2019-02-18 2021-10-14 Memorial Sloan-Kettering Cancer Center Combinations of multiple chimeric antigen receptors for immunotherapy
US20230348556A1 (en) 2019-02-21 2023-11-02 Arbele Limited Artificial immunosurveillance chimeric antigen receptor and cells expressing the same
WO2020181164A1 (en) 2019-03-06 2020-09-10 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
JP2022530211A (ja) 2019-04-22 2022-06-28 ナンジン レジェンド バイオテク カンパニー リミテッド 改変細胞及びその使用
AU2020262956A1 (en) * 2019-04-26 2021-12-16 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
JP2022533128A (ja) 2019-05-16 2022-07-21 ユニバーシティ オブ ワシントン Ｃａｒ ｔ細胞のｌｏｃｋｒ媒介性動員
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
CN112111012B (zh) 2019-06-20 2023-07-04 成都恩沐生物科技有限公司 共价多特异性抗体
WO2021003739A1 (zh) 2019-07-11 2021-01-14 武汉友芝友生物制药有限公司 四价对称双特异性抗体
CN112390891B (zh) 2019-08-14 2022-06-03 苏州方德门达新药开发有限公司 嵌合抗原受体及其构建方法和应用
WO2021030586A1 (en) 2019-08-15 2021-02-18 City Of Hope Dual bispecific antibody compounds and uses thereof
KR20240046306A (ko) * 2020-01-14 2024-04-08 신테카인, 인크. 편향된 il2 뮤테인 방법 및 조성물
AU2021237570A1 (en) * 2020-03-16 2022-09-08 Angeles Therapeutics, Inc. Novel antigen binding domains and synthetic antigen receptors incorporating the same
US20230104705A1 (en) 2020-03-17 2023-04-06 Cellular Biomedicine Group Inc. Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
US20230212255A1 (en) 2020-03-17 2023-07-06 Cellular Biomedicine Group Inc. Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
WO2022165461A1 (en) * 2021-01-27 2022-08-04 H. Lee Moffitt Cancer Center And Research Institute Inc. Bi-specific car t cells for b cell malignancies
AU2022233737A1 (en) * 2021-03-11 2023-09-28 Biosceptre (Aust) Pty Ltd Novel cell therapy system
MX2023015469A (es) * 2021-09-01 2024-01-19 Biosceptre Aust Pty Ltd Metodos y composiciones para estimular la actividad inmunitaria.

Also Published As

Publication number Publication date
US12233090B2 (en) 2025-02-25
US11253546B2 (en) 2022-02-22
FI3240805T3 (fi) 2025-02-17
US20220193136A1 (en) 2022-06-23
EP4400516A1 (en) 2024-07-17
ES3008782T3 (en) 2025-03-25
WO2016100232A1 (en) 2016-06-23
LT3240805T (lt) 2025-03-10
CA3008162A1 (en) 2016-06-23
EP3240805A1 (en) 2017-11-08
US20210145880A1 (en) 2021-05-20
US12053491B2 (en) 2024-08-06
US20170368098A1 (en) 2017-12-28
EP3240805A4 (en) 2018-05-09
EP3240805B1 (en) 2024-11-27
US20240261334A1 (en) 2024-08-08
SMT202500043T1 (it) 2025-03-12
US20240024359A1 (en) 2024-01-25
US11160833B2 (en) 2021-11-02
DK3240805T3 (da) 2025-02-10
US20240293463A1 (en) 2024-09-05
US12226435B2 (en) 2025-02-18

Similar Documents

Publication Publication Date Title
ES3008782T3 (en) Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
HK1259190A1 (zh) 嵌合抗原受體相關的方法和組合物
SG11201701297WA (en) Antibodies and chimeric antigen receptors specific for cd19
IL251537A0 (en) Human anti-ox40 antibodies and their uses
IL254254B (en) chimeric antigen receptor
IL250536A0 (en) Chimeric antigen receptors
IL252295A0 (en) Chimeric antigen receptors and methods of using them
IL251030A0 (en) Chimeric antigen receptors
ZA201605655B (en) Chimeric antigen receptors and methods of making
SG10201708896WA (en) Cd19 specific chimeric antigen receptor and uses thereof
SG11201606790XA (en) Chimeric antigen receptor
GB201503742D0 (en) Chimeric antigen receptor
IL258502A (en) psca-targeted chimeric antigen receptors
GB201617290D0 (en) Novel chimeric antigen receptors
ZA201703471B (en) Anti-cldn chimeric antigen receptors and methods of use
GB201519900D0 (en) Chimeric antigen receptor
ZA201508068B (en) Cd19 specific chimeric antigen receptor and uses thereof
GB201409761D0 (en) Chimeric antigen receptor
GB201403481D0 (en) Chimeric antigen receptor